Bullish Iovance Biotherapeutics Insiders Loaded Up On US$74.9m Of Stock
Quite a few insiders have dramatically grown their holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) over the past 12 months. An insider's optimism about the company's prospects is a positive si
M&A Is Back. 4 Stocks That Could Be Targets.
Mergers and acquisitions are on pace for a solid year. Small-cap biotech and tech look interesting.
The Case for Buying Iovance Biotherapeutics Stock Just Got Even Better. Here's Why
Iovance Biotherapeutics: A Strong Buy on Robust Clinical Data and Market Potential
HC Wainwright & Co. Reiterates Buy on Iovance Biotherapeutics, Maintains $32 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Iovance Biotherapeutics with a Buy and maintains $32 price target.
Iovance Biotherapeutics' Lifileucel Shows Promising Phase 2 Results: A Strong Buy Recommendation
Analysts Conflicted on These Healthcare Names: Iovance Biotherapeutics (IOVA), Amylyx Pharmaceuticals Inc (AMLX) and Vaxcyte (PCVX)
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Wells Fargo Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $25
Wells Fargo analyst Yanan Zhu maintains $Iovance Biotherapeutics(IOVA.US)$ with a buy rating, and maintains the target price at $25.According to TipRanks data, the analyst has a success rate of 41.3%
Analysts Are Bullish on These Healthcare Stocks: MacroGenics (MGNX), Iovance Biotherapeutics (IOVA)
What's Going On With Iovance Biotherapeutics Today?
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) stock is trading higher. The company recently announced updated clinical data for treating frontline advanced melanoma.What Happened: On Thursday, Iovance r
A Quick Look at Today's Ratings for Iovance Biotherapeutics(IOVA.US), With a Forecast Between $19 to $32
On May 24, major Wall Street analysts update their ratings for $Iovance Biotherapeutics(IOVA.US)$, with price targets ranging from $19 to $32.Barclays analyst Peter Lawson maintains with a buy rating,
Express News | Reported Earlier, Iovance To Present Updated Clinical Data For Lifileucel In Combination With Pembrolizumab In Frontline Advanced Melanoma At ASCO Annual Meeting
Piper Sandler Keeps Their Buy Rating on Iovance Biotherapeutics (IOVA)
Analysts Offer Insights on Healthcare Companies: Agenus (AGEN), Merus (MRUS) and Iovance Biotherapeutics (IOVA)
Iovance Biotherapeutics (IOVA) Gets a Buy From Barclays
Express News | Iovance Biotherapeutics Shares up 6.3% Premarket on Positive Updated Data From Mid-Stage Trial for Skin Cancer Treatment
Iovance Biotherapeutics to Present at Upcoming Conferences and Events
SAN CARLOS, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor in
Express News | Iovance Biotherapeutics Inc - Announced Updated Clinical Data for Lifileucel in Combination With Pembrolizumab in Frontline Advanced Melanoma
No Data